This is an old revision of the document!
Jesse Papenburg
Dr. Jesse Papenburg is a Canadian paediatric infectious diseases specialist and microbiologist based in Montreal, Quebec.
Education
Papenburg obtained his medical degree from McGill University and completed residency and subspecialty training at the Montreal Children's Hospital. He then completed a research fellowship on the molecular virology of RNA respiratory viruses at Laval University and a Master of Science in epidemiology at McGill.
Affiliations
Public Health Agency of Canada
Papenburg is a member of the National Advisory Committee on Immunization (NACI), responsible for approving the COVID-19 vaccines in Canada.1)
McGill University
Papenburg is an Assistant Professor of Paediatrics and an Associate Member of the Department of Epidemiology, Biostatistics and Occupational Health at McGill University. He practices Pediatric Infectious Diseases and Medical Microbiology at the Montreal Children's Hospital of the McGill University Health Centre.
COVID-19 Immunity Task Force
Papenburg is a scientific advisory on the secretariat of the COVID-19 Immunity Task Force.2) The CITF collaborates with the Coalition for Epidemic Preparedness Innovations (CEPI) on vaccine development.3)
Research
Papenburg's research is on the epidemiology of viral respiratory infections, with a focus on diagnostics to improve treatment and outcomes. He actively contributes to national and provincial guidelines on RSV immunoprophylaxis and influenza antiviral treatment.
COVID-19
Papenburg and Patricia Fontela are co-Primary Investigators in the CATCO-Kids study, investigating the use of hydroxychloroquine in children with COVID-19. The trial is funded by the Montreal Children's Hospital Foundation, and is a spinoff study from the CATCO trial, which is itself the Canadian branch of the SOLIDARITY Trial.4) 5) Papenburg and Fontela are also both investigators for CATCO, including investigating remdesivir.6)
Influenza
Papenburg has conducted research on influenza vaccines.7)
RSV
Papenburg was an author on an RSV study funded by the Bill & Melinda Gates Foundation.8) 9)
Funding
Papenburg is funded by a career award from Fonds de Recherche du Québec, and funding from the Quebec Ministry of Health and Social Services.10) He has received research funding from the CHUM Foundation and the Canadian Institutes of Health Research (CIHR). He has received grants from MedImmune and Sanofi, as well as grants and personal fees from AbbVie, BD Diagnostics, Janssen, and Seegene.11) 12) 13) He has also received consulting fees from Merck, and personal fees from Cepheid and Roche.14) 15) He has also published research funded by the Janeway Children's Hospital Foundation. He also served on a Scientific Steering Committee for AbbVie.16)
1)
National Advisory Committee on Immunization (NACI): Membership and representation. (2020, December 18). Wayback Machine; Government of Canada. https://web.archive.org/web/20201218222110/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html
2)
Labonne, S. Secretariat. COVID-19 Immunity Task Force. Retrieved April 19, 2022, from https://web.archive.org/web/20220322055327/https://www.covid19immunitytaskforce.ca/secretariat/
3)
Final Version Scientific Strategy, Governance, and Operational Plan. (2020). COVID-19 Immunity Task Force. https://web.archive.org/web/20220120225658/https://www.covid19immunitytaskforce.ca/wp-content/uploads/2020/11/CITF-Strategic-Plan_Final_ENG_FINAL_2.pdf#page=17
4)
Funded Research. COVID-19 Resources Canada. Retrieved April 19, 2022, from https://archive.ph/htYhS
5)
Results of MI4 Emergency COVID-19 Research Funding. (2021, August 23). McGill MI4. https://archive.ph/X6BWG
6)
Ali, K., Azher, T., Baqi, M., Binnie, A., Borgia, S., Carrier, F. M., Cavayas, Y. A., Chagnon, N., Cheng, M. P., Conly, J., Costiniuk, C., Daley, P., Daneman, N., Douglas, J., Downey, C., Duan, E., Duceppe, E., Durand, M., English, S., & Farjou, G. (2022). Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ: Canadian Medical Association Journal = Journal de l’Association Medicale Canadienne, cmaj.211698. https://doi.org/10.1503/cmaj.211698
7)
Baz, M., Papenburg, J., Hamelin, M., Ouakki, M., Skowronski, D. M., De Serres, G….Boivin, G. (2012). Seroconversion to Seasonal Influenza Viruses after A(H1N1)pdm09 Virus Infection, Quebec, Canada. Emerging Infectious Diseases, 18(7), 1132-1134. https://doi.org/10.3201/eid1807.111680.
8)
Scheltema, N. M., Gentile, A., Lucion, F., Nokes, D. J., Munywoki, P. K., Madhi, S. A., Groome, M. J., Cohen, C., Moyes, J., Thorburn, K., Thamthitiwat, S., Oshitani, H., Lupisan, S. P., Gordon, A., Sánchez, J. F., O’Brien, K. L., Gessner, B. D., Sutanto, A., Mejias, A., & Ramilo, O. (2017). Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series. The Lancet Global Health, 5(10), e984–e991. https://doi.org/10.1016/S2214-109X(17)30344-3
9)
University Medical Center Utrecht, Netherlands. (2016, April). Bill & Melinda Gates Foundation. https://archive.ph/yfvkp
10)
Gilca, R., Billard, M.-N., Zafack, J., Papenburg, J., Boucher, F. D., Charest, H., Rochette, M., & De Serres, G. (2020). Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada. Preventive Medicine Reports, 20, 101180. https://doi.org/10.1016/j.pmedr.2020.101180
11)
Papenburg, J., Mubareka, S., Allen, U. D., Skowronski, D., Stiver, H. G., Aoki, F. Y., & Evans, G. A. (2020). Guidance on the use of antiviral agents for the 2019–2020 influenza season. Official Journal of the Association of Medical Microbiology and Infectious Disease Canada, 5(2), 57–60. https://doi.org/10.3138/jammi.2020-01-13
12)
Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E., Manguiat, K., Lindsay, L. R., Wood, H., Drebot, M. A., Dibernardo, A., Zaharatos, G., Bazin, R., Gasser, R., Benlarbi, M., Gendron-Lepage, G., Beaudoin-Bussières, G., Prévost, J., Finzi, A., Ndao, M., & Yansouni, C. P. (2021). Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay. Open Forum Infectious Diseases, 8(6). https://doi.org/10.1093/ofid/ofab220
13)
Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E., Manguiat, K., Lindsay, L. R., Wood, H., Drebot, M. A., Dibernardo, A., Zaharatos, G., Bazin, R., Gasser, R., Benlarbi, M., Gendron-Lepage, G., Beaudoin-Bussières, G., Prévost, J., Finzi, A., Ndao, M., & Yansouni, C. P. (2021). Evaluation of a Commercial Culture-free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison with an Anti-RBD ELISA Assay. medRxiv. Preprint. https://doi.org/10.1101/2021.01.23.21250325
14)
Cheng, M. P., Papenburg, J., Desjardins, M., Kanjilal, S., Quach, C., Libman, M., Dittrich, S., & Yansouni, C. P. (2020). Diagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus 2. Annals of Internal Medicine, 172(11), 726–734. https://doi.org/10.7326/m20-1301
15)
Merckx, J., Cooke, S., El Tal, T., Bitnun, A., Morris, S. K., Yeh, E. A., Yea, C., Gill, P., Papenburg, J., Lefebvre, M.-A., Scuccimarri, R., Ulloa-Gutierrez, R., Brenes-Chacon, H., Yock-Corrales, A., Ivankovich-Escoto, G., Soriano-Fallas, A., Mezerville, M. H., Dewan, T., Restivo, L., & Nateghian, A. (2022). Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection: a multicentre cohort study. Canadian Medical Association Journal, 194(14), E513–E523. https://doi.org/10.1503/cmaj.210873
16)
Papenburg, J., & Harrison, R. (2021, October 27). Seasonal Influenza Immunization 2021-2022. National Collaborating Centre for Infectious Diseases. https://web.archive.org/web/20220419211302/https://nccid.ca/wp-content/uploads/sites/2/2021/12/DATAPOST-Rev-EN-Seasonal-Influenza-Webinar-2021-2022_Nov-23.LFpptm.pdf